Tango reports promising Phase 1/2 data for vopimetostat and daraxonrasib in pancreatic cancer
Tango Therapeutics presented significant results showing an 82% objective response rate for the vopimetostat and daraxonrasib combination in patients with metastatic pancreatic cancer. The company plans to initiate a registrational Phase 3 study in the first half of 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed